New hope for tough pancreatic cancer: drug duo tested
NCT ID NCT05558982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, BXCL701 and pembrolizumab, in 22 people with advanced pancreatic cancer that has spread. The goal is to see if this treatment can stop the cancer from growing for at least 18 weeks. Participants must have already tried one prior treatment and agree to two tumor biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Medstar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Smart drug delivers chemo directly to pancreatic cancer cells
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Could a stomach drug help fight pancreatic cancer?
- New hope for tough pancreatic cancer? drug combo targets KRAS mutations
- Experimental vaccine combo takes on tough pancreatic cancer